

# Key Information Document

## Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

## Product

### Rhenman & Partners Fund - Rhenman Healthcare Equity L/S a sub-fund of Rhenman & Partners Fund class IC2 (USD) - LU0417598520

This product is authorised in Luxembourg.

#### Manufacturer / Alternative investment fund manager

Name: FundRock Management Company S.A.

Contact details: Airport Center Building, 5 Heienhaff, L-1736 Senningerberg, Grand Duchy of Luxembourg  
[www.fundrock.com/funds/](http://www.fundrock.com/funds/) - Call +352 263 4561 for more information.

Competent Authority: The Commission de Surveillance du Secteur Financier is responsible for supervising the manufacturer in relation to this Key Information Document.

Date of production 04/02/2025

## What is this product?

#### Type

Investment Fund (F.C.P.), Luxembourg

#### Term

This sub-fund has no maturity date. However, the alternative investment fund manager may decide to close the sub-fund under certain circumstances.

#### Objectives

The sub-fund's objective is to create value for its investors, in the form of total return, with a focus on investments in the health sector. The sub-fund aims to perform better than traditional equity funds by both buying and short selling shares. Total return is achieved by investing in a global equity portfolio with a focus on health, equity derivatives, derivatives on equity indices, convertible bonds and exchange traded funds and other equity related derivative instruments, including swaps.

The sub-fund is not a UCITS and is comparable to a Swedish Special Fund (Specialfond). Fundamental analysis of the selected companies is used to select the investments, ie analysis of their business strategy, financial status and future projections. In addition, advice from experts in medical research may be sought as part of the decision making process. The sub-fund's portfolio of stocks is traded frequently as an integral part of the sub-fund's investment strategy.

The sub-fund may invest in money market instruments and other financial instruments for long periods and may invest up to 100% of its value in such instruments. The sub-fund may enter into currency derivative contracts to reduce its exposure to currency fluctuations.

The sub-fund may not invest more than 10% of its assets in other funds. The sub-fund's leverage, i.e. borrowing and derivatives exposure, may not exceed a total of 300% of the NAV.

**Benchmark:** The sub-fund is managed with reference to the EURIBOR 3M (the "Benchmark") for the purpose of performance fee calculation only.

#### Intended retail investor

This product is suitable for institutional investors who would invest in specific portfolio of assets. Each portfolio of assets will be invested for benefit of relevant subfund. Investors must be prepared to accept volatility and potential capital losses and may therefore be inappropriate for investors who plan to withdraw

their money within five years.

#### Other information

**Depository:** Skandinaviska Enskilda Banken. AB (publ) – Luxembourg Branch

**Dividend income:** This class is a capitalisation class meaning that income is reinvested.

**Conversion right:** The investor has the right to convert his investment in units in one sub-fund for units in the same sub-fund or in another sub-fund. The investor can obtain information about how to convert in the prospectus of the fund.

**Segregation:** The assets and liabilities of a sub-fund are segregated pursuant to the law so that the commitments and liabilities of one sub-fund do not affect the other sub-funds.

**Additional information:** Additional information about the fund, copies of its prospectus, the latest annual and semi-annual report and the latest prices of units may be obtained free of charge from the alternative investment fund manager or on [www.fundrock.com/funds/](http://www.fundrock.com/funds/). The prospectus and the periodic reports are prepared for the entire fund and are available in English. The alternative investment fund manager may inform you about other languages in which these documents are available.

This sub-fund was launched in 2009 and this unit class in 2014.

The reference currency of the sub-fund is expressed in EUR. The currency of the unit class is expressed in USD. For this unit class, the foreign-exchange risk of the unit currency is not hedged against the sub-fund's reference currency.

#### Additional information for investors in Switzerland

The state of the origin of the fund is Luxembourg. The representative in Switzerland is FundRock Switzerland SA, Route de Cité-Ouest 2, 1196 Gland, Switzerland. The paying agent in Switzerland is Banque Cantonale de Genève, 17, quai de l'Île, 1204 Geneva, Switzerland. The Prospectus, the Articles of Association and annual and semi-annual report, if any can be obtained free of charge from the representative in Switzerland. With regards to the shares offered in Switzerland, the place of performance is the registered office of the representative and the place of jurisdiction is at the registered office of the representative or at the registered office or place of residence of the investor. The risk indicator and the performance scenarios were calculated and presented in accordance with the regulations of the fund's home country.

# What are the risks and what could I get in return?

## Risk indicator



The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 5 out of 7, which is a medium-high risk class. This rates the potential losses from future performance at a medium-high level, and poor market conditions will likely impact our capacity to pay you.

**Be aware of currency risk.** You may receive payments in a currency that differs from your reference currency, so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.

The sub-fund is also exposed to the following materially relevant risks that are not included in the summary risk indicator: Credit risk, derivatives risk, liquidity risk, political risk, operational risk.

This product does not include any protection from future market performance so you could lose some or all of your investment.

If we are not able to pay you what is owed, you could lose your entire investment.

## Performance scenarios

**Recommended holding period: 5 years**

**Example investment: 10.000 USD**

		<b>If you exit after 1 year</b>	<b>If you exit after 5 years (recommended holding period)</b>
<b>Scenarios</b>			
<b>Minimum</b>	<b>There is no minimum guaranteed return. You could lose some or all of your investment.</b>		
<b>Stress</b>	<b>What you might get back after costs</b>	4.920 USD	3.420 USD
	Average return each year	-50,8 %	-19,3 %
<b>Unfavourable</b>	<b>What you might get back after costs</b>	7.580 USD	10.640 USD
	Average return each year	-24,2 %	1,2 %
<b>Moderate</b>	<b>What you might get back after costs</b>	11.270 USD	17.060 USD
	Average return each year	12,7 %	11,3 %
<b>Favourable</b>	<b>What you might get back after costs</b>	16.670 USD	27.580 USD
	Average return each year	66,7 %	22,5 %

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate and favourable scenarios shown are illustrations using the worst, average, and best performance of the product over the last 10 years. Markets could develop very differently in the future.

Unfavourable scenario: This type of scenario occurred for an investment between August 2021 and December 2024.

Moderate scenario: This type of scenario occurred for an investment between June 2019 and June 2024.

Favourable scenario: This type of scenario occurred for an investment between October 2016 and October 2021.

The stress scenario shows what you might get back in extreme market circumstances.

## What happens if FundRock Management Company S.A. is unable to pay out?

The Management Company is responsible for administration and management of the sub-fund, and does not typically hold assets of the sub-fund (assets that can be held by a depositary are, in line with applicable regulations, held with a depositary in its custody network). The Management Company, as the PRIIPS manufacturer has no obligation to pay out since the product design does not contemplate any such payment being made. However, investors may suffer loss if the sub-fund or the depositary is unable to pay out. There is no compensation or guarantee scheme in place which may offset, all or any, of this loss.

## What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

### Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding period we have assumed the product performs as shown in the moderate scenario
- 10.000 USD is invested

	If you exit after 1 year	If you exit after 5 years
<b>Total costs</b>	255 USD	2.048 USD
Annual cost impact (*)	2,6 %	2,6 % each year

(\*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 13,9% before costs and 11,3% after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

### Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
<b>Entry costs</b>	We do not charge an entry fee for this product.	0 USD
<b>Exit costs</b>	We do not charge an exit fee for this product.	0 USD
<b>Ongoing costs taken each year</b>		
<b>Management fees and other administrative or operating costs</b>	1,6% of the value of your investment per year. This is an estimate based on actual costs over the last year.	162 USD
<b>Transaction costs</b>	0,9% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	93 USD
<b>Incidental costs taken under specific conditions</b>		
<b>Performance fees</b>	20% of the increase in the value of the units, subject to specific conditions. The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years.	0 USD

A maximum conversion fee of 3,0% is charged for the conversion of part or all of the units.

## How long should I hold it and can I take money out early?

### Recommended holding period: 5 years

You should be prepared to stay invested for 5 years. However, you can redeem your investment without penalty at any time during this time, or hold the investment longer. Redemptions are possible on a monthly basis. In exceptional circumstances, your right to request the redemption of your investment may be limited or suspended.

## How can I complain?

Complaints about the behaviour of the person who advised you on the product or sold it to you, should be addressed directly to that person. Complaints about the product or the behaviour of the manufacturer of this product should be directed to the following address:

Postal address: FundRock Management Company S.A., Attention: Complaints Handling, Airport Center Building, 5 Heienhaff, L-1736 Senningerberg, Grand Duchy of Luxembourg.

E-mail: [FRMC\\_qualitycare@fundrock.com](mailto:FRMC_qualitycare@fundrock.com)

Website: <https://www.fundrock.com/policies-and-compliance/complaints-policy/>

In all cases, the complainant must clearly indicate his/her contact details (name, address, phone number or email address) and provide a brief explanation of the claim.

## Other relevant information

The prospectus, the latest version of the Key Information Document as well as the latest annual and semi-annual report, may be obtained free of charge on [www.fundrock.com/funds/](http://www.fundrock.com/funds/).

*Past performance and previous performance scenarios:* Historical returns for the last 9 years and previously published performance scenarios, updated on a monthly basis, are available on <https://www.yourpriips.eu/site/6724/en-CH>.